Company’s 36-month beta value is 0.68.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AADI is 17.38M, and currently, short sellers hold a 6.34% ratio of that floaft. The average trading volume of AADI on May 09, 2024 was 345.43K shares.
AADI) stock’s latest price update
Aadi Bioscience Inc (NASDAQ: AADI) has experienced a decline in its stock price by -12.80 compared to its previous closing price of 2.11. However, the company has seen a fall of -5.15% in its stock price over the last five trading days. PRNewsWire reported 2024-05-01 that Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES, May 1, 2024 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the “Investors & News” page of the Aadi Bioscience website at aadibio.com.
AADI’s Market Performance
AADI’s stock has fallen by -5.15% in the past week, with a monthly drop of -12.38% and a quarterly rise of 5.14%. The volatility ratio for the week is 10.95% while the volatility levels for the last 30 days are 7.31% for Aadi Bioscience Inc The simple moving average for the last 20 days is -3.21% for AADI’s stock, with a simple moving average of -48.54% for the last 200 days.
Analysts’ Opinion of AADI
Jefferies, on the other hand, stated in their research note that they expect to see AADI reach a price target of $45. The rating they have provided for AADI stocks is “Buy” according to the report published on January 11th, 2022.
AADI Trading at -10.41% from the 50-Day Moving Average
After a stumble in the market that brought AADI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.60% of loss for the given period.
Volatility was left at 7.31%, however, over the last 30 days, the volatility rate increased by 10.95%, as shares sank -8.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.11% lower at present.
During the last 5 trading sessions, AADI fell by -5.15%, which changed the moving average for the period of 200-days by -68.38% in comparison to the 20-day moving average, which settled at $1.89. In addition, Aadi Bioscience Inc saw -8.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AADI starting from Desai Neil, who sale 40,000 shares at the price of $1.93 back on May 01 ’24. After this action, Desai Neil now owns 1,331,543 shares of Aadi Bioscience Inc, valued at $77,184 using the latest closing price.
Desai Neil, the EXECUTIVE CHAIRMAN of Aadi Bioscience Inc, sale 22,228 shares at $2.23 during a trade that took place back on Apr 02 ’24, which means that Desai Neil is holding 1,371,543 shares at $49,513 based on the most recent closing price.
Stock Fundamentals for AADI
Current profitability levels for the company are sitting at:
- -2.95 for the present operating margin
- 0.88 for the gross margin
The net margin for Aadi Bioscience Inc stands at -2.64. The total capital return value is set at -0.68. Equity return is now at value -58.22, with -48.86 for asset returns.
Based on Aadi Bioscience Inc (AADI), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -8.49. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -625.5.
Currently, EBITDA for the company is -71.76 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of -0.44. The receivables turnover for the company is 4.44for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.16.
Conclusion
In a nutshell, Aadi Bioscience Inc (AADI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
